The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)
Purpose of Review
To review terminology, diagnostic algorithms, and clinical outcomes for patients with unexplained blood cytopenias.
Patients with cytopenias that remain unexplained after organized diagnostic testing can be described as having “idiopathic cytopenias of undetermined significance” (ICUS). Patients with unexplained cytopenias have a risk of progression to clonal myeloid neoplasms, including myelodysplastic syndromes (MDS). If a somatic mutation in a gene associated with leukemia is detectable in hematopoietic tissue, especially if multiple mutations with a high (> 10%) variant allele frequency are present, the risk of progression to frank neoplasia is greater than if such mutations are not detected. These patients can be described with the term, “clonal cytopenias of undetermined significance” (CCUS). CCUS patients have a natural history similar to lower-risk MDS.
For patients with unexplained cytopenias, longitudinal follow-up including serial monitoring of blood counts is appropriate in view of the progression risk. Genetic testing may aid in risk stratification.
KeywordsCytopenias Next-generation sequencing Myelodysplastic syndromes Clonal hematopoiesis Ineffective hematopoiesis Diagnostic testing
Compliance with Ethical Standards
Conflict of Interest
Dr. Steensma declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.• Wouters H, van der Klauw MM, de Witte T, et al. Association of anemia with health-related quality of life and survival: a large population-based cohort study. Haematologica. 2019;104:468–76 Population-based analysis that confirms that even mild anemia is a risk factor for morbidity and mortality.PubMedPubMedCentralCrossRefGoogle Scholar
- 9.•• Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371–8 This important analysis of 683 patients with unexplained cytopenias using a 40-gene sequencing assay established that CCUS confers a much greater risk of progression to WHO-diagnosable MDS or another myeloid malignancy than ICUS.PubMedPubMedCentralCrossRefGoogle Scholar
- 12.•• Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8:73483–500 Minimal diagnostic criteria for MDS have been proven challenging to be defined, given the vast shadowlands of clonal states and idiopathic cytopenias in between health and overt disease. This consensus recommendation from an expert panel outlines appropriate diagnostic evaluation in patients with unexplained cytopenias and which features support a diagnosis of MDS.PubMedPubMedCentralGoogle Scholar
- 14.Jain M, Tripathi A. ICUS/CCUS/CHIP: basics & beyond. Expert Rev Hematol. 2017:1–6.Google Scholar
- 21.Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res 2018.Google Scholar
- 33.Guralnik JM, Ershler WB, Schrier SL, Picozzi VJ. Anemia in the elderly: a public health crisis in hematology. Hematology Am Soc Hematol Educ Program. 2005:528–32.Google Scholar
- 39.•• Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126:2355–61 In patients with ICUS, DNA mutations are common, especially SF3B1 mutations in patients with ring sideroblasts. This analysis influenced the World Health Organization re-definition of MDS with ring sideroblasts to include a lower proportion of ring sideroblasts (5% or more instead of 15%) if SF3B1 mutations are present.PubMedPubMedCentralCrossRefGoogle Scholar
- 43.• Cargo C, Cullen M, Taylor J, et al. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood. 2019;133:1325–34 Monocytosis is a risk factor for development of the MDS/MPN overlap neoplasm chronic myelomonocytic leukemia (CMML). This DNA and flow cytometry analysis demonstrates that when somatic mutations are present; the risk of progression to overt CMML is substantial, regardless of conventional pathological findings.PubMedCrossRefGoogle Scholar
- 49.Medyouf H. The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. Blood. 2017.Google Scholar
- 51.•• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21 Clinical data and murine models support the concept of clonal hematopoiesis as a risk factor for cardiovascular disease, including myocardial infarction and stroke. It is unclear if this risk is limited to CHIP or extends to CCUS.PubMedPubMedCentralCrossRefGoogle Scholar
- 53.Ridker PM, Narula J. Will reducing inflammation reduce vascular event rates? JACC Cardiovasc Imaging 2017.Google Scholar
- 54.Steensma DP, Stone RM, “Myelodysplastic syndromes”, chapter 96 (pp. 1798–1820) In Abeloff’s Clinical Oncology, 6th edition, Philadelphia: Elsevier, edited by John E. Niederhuber, James O. Armitage, James H. Doroshow, Michael B. Kastan and Joel E. Tepper, published 2019Google Scholar